Healthy Volunteers Bioavailability Study
Conditions
Keywords
bioavailability, pharmacokinetics, I phase, AZD6244, cancer
Brief summary
To assess the absolute bioavailability of oral selumetinib in healthy male volunteers
Interventions
3 capsules of 25 mg given as a single dose
OTHER[14C] selumetinib IV solution
single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
Sponsors
AstraZeneca
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of written informed consent 2. Healthy male volunteers aged 18 to 65 3. Male volunteers with sexual partners who are pregnant or who could become pregnant should use two highly effective methods of contraception (including one barrier method) for at least 14 days after completing the study and should avoid sperm donation for 14 days after study completion. 4. Body mass index between 18 and 30 kg/m2 and weighing between 50 and 100 kg. 5. Use no nicotine containing products for at least 3 months prior to screening with a negative cotinine screen at screening and Day 1 (Visit 2) 6. Calculated creatinine clearance greater than 50 mL/min using Cockcroft Gault formula.
Exclusion criteria
1. Involvement in the planning and/or conduct of the study 2. Previous enrolment for treatment in the present study 3. Japanese or non Japanese Asian or Indian ethnicity. 4. Any one parent or grandparent is Japanese or non-Japanese Asian or Indian. 5. Treatment with another new chemical entity or participation in any other clinical study that included drug treatment within at least 3 months 6. Participation in another clinical study involving administration of \[14C\] radioactivity within 1 year. 7. Current or past history of central serious retinopathy or retinal vein thrombosis, intraocular pressure greater than 21 mmHg or uncontrolled glaucoma. 8. Any clinically significant disease or disorder which, may put the volunteer at risk because of participation in the study, influence the study result or influence the volunteer's ability to participate in the study. 9. Any clinically relevant abnormal findings in physical examination, haematology, clinical chemistry, urinalysis, vital signs or 12 lead ECG at Visit 1, which may put the volunteer at risk because of his participation in the study. 10. Use of drugs with enzyme inducing properties such as St John's Wort within 4 weeks prior to the administration of the investigational product 11. Use of any other prescribed medicine and over the counter drugs within 2 week or 5 times the half life, whichever is longer prior to the administration of the investigational product up to and including the follow up visit (Visit 4), with the exception of occasional use of paracetamol or ibuprofen and over the counter adrenergic nasal spray. No medications known to prolong the QT/corrected QT interval are allowed. 12. Excessive intake of caffeine containing drinks or food 13. Any intake of grapefruit and Seville oranges including products containing grapefruit or Seville oranges within 7 days of the admission on Day -1. 14. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to Selumetinib. 15. Plasma donation within 1 month of screening (Visit 1) or any blood donation or blood loss greater than 500 mL during the 3 months prior to screening (Visit 1). 16. History of or current alcohol or drug abuse. 17. A suspected or manifested infection according to the International Air Transport Association Categories A and B infectious substances. 18. Positive results on screening tests for HIV and/or hepatitis B and/or hepatitis C. 19. Baseline LVEF \<55% measured by echocardiography. 20. Planned inpatient surgery, dental procedure or hospitalisation during the study. 21. Healthy male volunteers who in the opinion of the Principal Investigator, should not participate in the study. 22. Judgment by Principal Investigator that the volunteer should not participate in the study if they have ongoing or recent minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Absolute Bioavailability | 0 to 72 hours post-dose | To calculate absolute bioavailability we used the formula: Area Under the Curve (oral dose)/Area Under the Curve (intravenous dose)\*100 |
Countries
United Kingdom
Participant flow
Recruitment details
21 subjects were enrolled, 12 of these subjects went on to receive treatment
Participants by arm
| Arm | Count |
|---|---|
| Selumetinib Patients received a single oral dose of selumetinib 75mg followed by IV carbon 14 selumetinib (80 micrograms) 1 hour 15 minutes after receiving the oral dose. | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | Selumetinib |
|---|---|
| Age, Continuous | 42 Years STANDARD_DEVIATION 11 |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 2 / 12 |
| serious Total, serious adverse events | 0 / 12 |
Outcome results
Primary
Absolute Bioavailability
To calculate absolute bioavailability we used the formula: Area Under the Curve (oral dose)/Area Under the Curve (intravenous dose)\*100
Time frame: 0 to 72 hours post-dose
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Selumetinib | Absolute Bioavailability | 62.1 % of bioavailability |